Courage Therapeutics

2:15 PM - 2:30 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Courage Therapeutics is a pre-clinical biotech company focused on feeding behavior. The company has established a platform for creating receptor subtype specific products to activate or block melanocortin pathway signaling. The company was founded to treat eating disorders such as anorexia nervosa and is a spin out of Dr. Roger Cone’s lab at work he University of Michigan. The Courage platform has established a series of proprietary clinical candidates with potent MC4R activity and MC3R antagonist activity to treat obesity and binge eating disorder. Courage is seeking to continue to develop additional orexigenic applications to support patients with challenges maintaining body weight due to metabo-psychiatric disorders.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
MC4R agonist for treatment of obesity (licensing program planned). MC3R agonist for treatment of anorexia nervosa
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Placeholder Photo
Courage Therapeutics